Evaluating how feasible a new mobile phone application is for reducing sitting behaviour and improving blood sugar levels in Type 2 diabetes

Not Applicable

Completed

• Conditions: Nutritional, Metabolic, Endocrine; Type 2 diabetes; Type 2 diabetes mellitus

• Registration Number: ISRCTN11167977
• Lead Sponsor: niversity of Bedfordshire

Brief Summary

2020 results in https://doi.org/10.3390/ijerph17124414 (added 29/06/2020)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2017-07-06
• Study Completion: 2018-03-01
• Last Update Posted: 13 July 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

1. Male or female
2. Aged 18-65 years
3. Diagnosed with Type 2 diabetes in the last 4 years
4. In the first stage (single non-insulin blood glucose lowering therapy) or first intensification (dual treatment of metformin plus one other drug) of drug treatment or using a diet and exercise management strategy
5. Speak and read English
6. Body mass index (BMI) < 40 kg/m2

Exclusion Criteria

1. Type 1 diabetes
2. Diseases or disorders related to diabetes (e.g. heart disease, damage to the retina at the back of the eye, kidney problems, and infections, ulcers or reduced ability to feel pain in feet)
3. Type 2 diabetes diagnosed more than 4 years ago
4. Pregnant
5. Severe obesity

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<br> 1. Sedentary behaviour, measured using ActivPAL activity monitor at baseline and during the final week of the 8 week intervention<br> 2. Oral glucose tolerance, measured using Oral Glucose Tolerance Test (OGTT) at baseline and post-intervention (8 weeks)<br>

Secondary Outcome Measures

Name	Time	Method
<br> 1. Physical activity, measured using ActivPAL activity monitor at baseline and during the final week of the 8 week intervention<br> 2. Body fat, measured using bioelectrical impedance analysis and waist circumference at baseline and post-intervention (8 weeks)<br> 3. Blood pressure, measured using using an automated oscillatory device at baseline and post-intervention (8 weeks)<br> 4. Sedentary behaviour self-efficacy, measured using an adapted version of the Schwarzer and Renner (2007) Physical Exercise Self-Efficacy Scale at baseline and post-intervention (8 weeks)<br> 5. Current mood, measured using the short Positive and Negative Affect Scale (PANAS) at baseline and post-intervention (8 weeks)<br> 6. Psychological wellbeing, assessed using the National Wellbeing Measurement and the Warwick Edinburgh Mental Well-Being Scale (WEMWBS) at baseline and post-intervention (8 weeks)<br>